In 2021, the WHO classification of central nervous system tumors was further modified to define GBM as IDH-wildtype, WHO grade 4, whereas WHO grade 4 tumors with IDH mutation were reclassified as astrocytomas [13]. Here, IDH1 is linked to glioblastoma.